| scholarly article | Q13442814 |
| P50 | author | Bruce Barton | Q43146506 |
| Jean P. Molleston | Q87417017 | ||
| P2093 | author name string | Michael R Narkewicz | |
| Philip Rosenthal | |||
| Kathleen B Schwarz | |||
| Barbara Haber | |||
| Karen F Murray | |||
| Zachary D Goodman | |||
| Parvathi Mohan | |||
| Regino P Gonzalez-Peralta | |||
| P2860 | cites work | High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin | Q33388409 |
| Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial | Q34194979 | ||
| The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. | Q34588247 | ||
| Fibrosis and disease progression in hepatitis C. | Q34984040 | ||
| Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study | Q35596325 | ||
| Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. | Q35598407 | ||
| Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. | Q35770548 | ||
| Clinical spectrum and histopathologic features of chronic hepatitis C infection in children | Q35915663 | ||
| Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection | Q37126749 | ||
| Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. | Q37126762 | ||
| Chronic viral hepatitis in children: any role for the pathologist? | Q37193214 | ||
| NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents | Q38001268 | ||
| Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection | Q40137082 | ||
| Progression of liver fibrosis among injection drug users with chronic hepatitis C. | Q40339820 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in children and adolescents | Q40361081 | ||
| Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease | Q42978075 | ||
| Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth | Q42982808 | ||
| Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening | Q42995334 | ||
| Clinical and histologic features of chronic hepatitis C virus infection after blood transfusion in Japanese children | Q42996780 | ||
| Fibrosis in chronic hepatitis C acquired in infancy: is it only a matter of time? | Q43049178 | ||
| Chronic hepatitis C in children: the pathological and clinical spectrum. | Q44114941 | ||
| Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease | Q44244167 | ||
| Progression of fibrosis in chronic hepatitis C. | Q44269259 | ||
| Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection | Q45227676 | ||
| Fibrosis progression rates between chronic hepatitis B and C patients with elevated alanine aminotransferase levels | Q46502465 | ||
| Sampling variability of liver fibrosis in chronic hepatitis C. | Q48583601 | ||
| Treatment of hepatitis C in children. | Q50560594 | ||
| Hepatitis C in children | Q73413518 | ||
| Changes in liver histopathology in women infected with hepatitis C through contaminated anti-D immunoglobulin injections in Ireland | Q74346226 | ||
| Histopathology of the liver in children with chronic hepatitis C viral infection | Q77485792 | ||
| Hepatocellular carcinoma in 2 young adolescents with chronic hepatitis C | Q83763566 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | liver disease | Q929737 |
| hepatitis C | Q154869 | ||
| chronic hepatitis C | Q55779873 | ||
| chronic hepatitis | Q62019625 | ||
| P304 | page(s) | 1580-1586 | |
| P577 | publication date | 2013-09-30 | |
| P1433 | published in | Hepatology | Q15724398 |
| P1476 | title | Evaluating progression of liver disease from repeat liver biopsies in children with chronic hepatitis C: a retrospective study | |
| P478 | volume | 58 |
| Q58788714 | 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C |
| Q91896301 | Advanced liver disease in Russian children and adolescents with chronic hepatitis C |
| Q37406708 | Disease progression in Chinese patients with hepatitis C virus RNA-positive infection via blood transfusion |
| Q40178123 | Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan |
| Q37098372 | HCV treatment in children and young adults with HIV/HCV co-infection in Europe |
| Q91801771 | Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection |
| Q93080853 | Hepatitis C virus infection in children and adolescents |
| Q40824296 | High Response Rate to Pegylated Interferon Alpha and Ribavirin Combination Therapy in Hemophilic Children with Chronic Hepatitis C; A Case-Control Study |
| Q38552521 | Histopathology of hepatitis C in children, a systematic review: implications for treatment |
| Q30398796 | Is liver biopsy still needed in children with chronic viral hepatitis? |
| Q26752471 | KASL clinical practice guidelines: management of hepatitis C |
| Q51836024 | KASL clinical practice guidelines: management of hepatitis C. |
| Q92904932 | Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C |
| Q37613361 | Liver steatosis in children with chronic hepatitis B and C: Prevalence, predictors, and impact on disease progression |
| Q99579331 | Management of hepatitis C in children and adolescents during COVID-19 pandemic |
| Q35100262 | The influence of hepatitis B and C virus coinfection on liver histopathology in children |
| Q91940758 | Treating HCV infection in children |
| Q26851883 | Treating hepatitis C virus in children: time for a new paradigm |
| Q26773285 | Vertically acquired hepatitis C virus infection: Correlates of transmission and disease progression |
| Q26782000 | What's new in hepatitis C virus infections in children? |
Search more.